Latest Projections: Following Release Of Rx Harvest's 100% Natural Enhancement Treatment Latteno Food (LATF) To Be Featured in Playboy Magazine Article Scheduled For July Edition Predicts Sierra World Equity Review.
Monday May 19th 2014
Special ALERT From The Office Of The Publisher Of Sierra World Equity Review
GeoVax (GOVX)
Welcome, our latest Publisher Alert #15 is GeoVax (GOVX) a small under the radar biotech but the LEADER in HIV vaccine development with FDA approved late stage clinical trials!
With over 1 million visitors to our blog and sites and thousands of visitors daily Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our Next PUBLISHER ALERT # 15, GeoVax (GOVX) the share price is only going to rise!
Sierra's Publisher CHERRY picks only the very best stocks for our Publisher Alerts, join us as we continue the hottest streak now with 14 WINNERS in a row, thanks to the POWER OF EXPOSURE on Sierra World Equity Review.
Here is WHY Sierra's Publisher has initiated a long position in GeoVax (GOVX) with information taken from the company's website, SEC filings and recent official press releases.
GeoVax (GOVX) is a biotechnology company specializing in the creation, development, and commercialization of human vaccines to combat HIV/AIDS.
BUT IT GETS EVEN BETTER:
GeoVax (GOVX) has the LEADING and most promising HIV vaccine (GOVX-B11) available, with LATE STAGE clinical trials. (That is HUGE!)
Atlanta Business Chronicle - "Atlanta-based HIV/AIDS vaccine developer GeoVax Labs Inc. (OTC QB: GOVX) is prepping for discussions pharma and biotechs about collaboration on the commercialization of its HIV/AIDS vaccines"
GeoVax (GOVX) Big Pharma partnership coming, groundwork being laid! At the 15th annual Bio Convention Robert McNally, President and CEO of GeoVax stated in an interview that GeoVax had 7 meetings before 1030am in the partnering arena.
GeoVax (GOVX) has developed proprietary innovative technology, the GeoVax HIV vaccines are for use in both preventive and therapeutic programs with advance human clinical trials having yielded positive data. ( Advanced human trials with positive results is a VERY BIG DEAL!)
GeoVax (GOVX) unique AIDS vaccine technology is designed for use in uninfected people to protect them from AIDS, while recently completed non-human studies provide data to indicate GeoVax vaccines will also prove an effective treatment for those already infected. ( An HIV/AIDS Vaccine that can prevent you from getting infected WHILE simultaneously treating those already infected and it is in late stage trials.....That is HUGE!)
GeoVax (GOVX) HIV vaccine candidates are flourishing in their development while other biotechs continue to have failures in their HIV/AIDS vaccine clinical programs. In fact the FDA was so impressed with GeoVax HIV vaccine candidate results they green lighted the vaccine candidate to a phase 2b efficacy trial. (That is HUGE!)
GeoVax (GOVX) HIV vaccine candidate (GOVX-B11) has completed Phase 2a with FDA sanctioned Phase 2b efficacy trials in planning discussions with the U. S. National Institutes of Health (NIH) and the HIV Trials Network (HVTN), these are THE ONLY HIV vaccines for America and Europe that entering efficacy trials. (Out of all the biotech companies in the world GeoVax is the ONLY one with Phase 2b efficacy clinical trials about to start... A VERY BIG DEAL!)
BUT IT GETS EVEN BETTER:
GeoVax (GOVX) is backed by U. S. National Institutes of Health (NIH) that has provided GeoVax with many millions to fund research and clinical trail and preventative clinical trials, most small biotechs would covet this kind of financial backing!
GeoVax (GOVX) It's been a long road, GeoVax HIV/AIDS vaccine technologies and extensive patent filings evolved over 15 years through a collaboration headed by Dr. Harriet Robinson at Emory University in Atlanta, Georgia, with researchers at the U. S. National Institutes of Health (NIH) and the U. S. Center for Disease Control and Prevention (CDC)
GeoVax (GOVX) current propriety HIV/AIDS vaccine pipeline drugs:
For Use in the America's and Western Europe:
-GOVX-B11 vaccine preventative now in Phase 2b planning with the U. S. National Institutes of Health (NIH) and the HIV Trials Network (HVTN) having successfully completed preclinical, phase1 and phase 2a clinical trials
-GOVX-B11 therapeutic phase 2 to start having successfully completed preclinical and phase 1 trials
-GOVX-B21 therapeutic phase 1 to start, preclinical successfully completed
Targeting 3rd World Countries:
-GOVX-C11 preventive vaccine currently under U. S. National Institutes of Health (NIH) grant development
-GOVX-C21 therapeutic vaccine currently under U. S. National Institutes of Health (NIH) grant development
BUT IT GETS EVEN BETTER:
GeoVax (GOVX) at the end of fiscal year 2013 had NO DEBTS on it's books, unheard of for a small biotech, thanks to government grants and support from U. S. National Institutes of Health (NIH)
GeoVax (GOVX) in 2013 GeoVax generated grant revenues of $2.4 million
GeoVax (GOVX) also reported approximately $822,000 in unused grant funds available for use as of December 31, 2013
GeoVax (GOVX) at the end of it's fiscal year on December 31 2013, GeoVax held $2.5 million in cash, an increase of $1.5 million from the previous year. Very Healthy!!
GeoVax (GOVX) with continued success in Phase II trials for it's preventive HIV vaccine, look for a big pharmaceutical partnership to assist in the commercialization of it's patented vaccines technology.
GeoVax (GOVX) GeoVax protects it's AIDS vaccine technology with a major Patent Portfolio, it has:
-Five patents controlling the AIDS vaccine manufacturing process.
-Five issued U.S. patents and Two U.S. filed patent applications related to MVA vector vaccine technology. Licensed from the NIH, these are key licensed patents for the use of MVA as a method for delivering GeoVax's HIV-1 antigens as an AIDS vaccine.
-One issued U.S. patent and three U.S. filed patent applications covering the DNA vector vaccine.
-29 additional licensed or filed patents in the USA and several other key countries on various components and compositions of our GeoVax's vaccine
BUT IT GETS EVEN BETTER:
GeoVax (GOVX) is trading near HISTORIC LOWS currently under 40 cents a share, NOW is the time to BUY, Sierra's publisher believes that soon GeoVax will be trading at many times it's current price!
GeoVax (GOVX) on March 19th 2014 highly respected Zachs Small Cap Research issued an OUTPERFORM rating (essentially a BUY rating) on GeoVax giving it a 12-month price target of $1.50. Now can you see just how undervalued GeoVax is, even the Zachs rating reflects a potential 500% increase coming to GeoVax.
GeoVax (GOVX) has only 24.97M shares outstanding with a super low float of 18.85M shares (that means the share price could move up very quickly)
GeoVax (GOVX) from an investment standpoint with millions of people sadly infected with HIV/AIDS worldwide along with approximately 60 000 thousand new cases reported in the United States each year, BUYING GeoVax (GOVX) NOW is a NO_BRAINER!
With it's leading HIV vaccine (GOVX-B11) and currently THE most promising HIV vaccine under development in late stage human trials, the amazing value here is clear with potentially HUGE revenue streams coming to GeoVax in the future!
Watch this company overview and informative short 3 minute clip presented by GeoVax President and CEO Robert McNally
What a great way to start off our new series of Publisher ALERTS, showing the POWER OF EXPOSURE on Sierra World Equity Review.
-Sierra's Publisher ALERT # 1 Vystar Corporation (VYST) had gains over 100%
-Sierra's Publisher ALERT # 2 Vista International Technologies (VVIT) had gains over 100%
-Sierra's Publisher ALERT # 3 VeriTeQ Corporation (VTEQ) had gains over 30%
-Sierra's Publisher ALERT # 4_Dolphin Digital Media (DPDM) surged over 55%
-Sierra's Publisher ALERT # 5_Powerdyne International (PWDY) ran up over 37%
-Sierra's Publisher ALERT # 6_The Digital Development Group (DIDG) ran up over 32%
-Sierra's Publisher ALERT # 7_AJ Greentech Holdings (AJGH) ran up over 35%
-Sierra's Publisher ALERT # 8 On The Move Systems (OMVS) soared almost 50%
-Sierra's Publisher ALERT # 9 Broadview Institute (BVII) quick gains of over 31%
-Sierra's Publisher ALERT # 10 Global Water Technologies (GWTR)_rose over 40%
-Sierra's Publisher ALERT # 11 Lexaria Corp. (LXRP) quick gains of 24%
-Sierra's Publisher ALERT # 12 Big Tree Group (BIGG) gained 50%
-Sierra's Publisher ALERT # 13 Optex Systems Holdings (OPXS) gained over 25%
-Sierra's Publisher ALERT # 14 TaxuCardium Pharmaceuticals (CRXM) gains over 30%
.
About Our Special Publisher ALERTS
During 2014, as a measure of appreciation to our readership, the publisher of Sierra World Equity Review has decided to give Sierra's loyal readers the heads up once or twice a week on stocks that he has taken a position in, they are flying low under the radar and that are on the verge of breaking out and potentially being a 10 bagger from when Sierra's Publisher issues the ALERT!
About Sierra World Equity Review
Using complex proprietary algorithms in our price targets and ratings Sierra World Equity Review makes accurate calls! We now update our 10 day short term price targets and BUY or SELL ratings for each stock every 14 days.
Sierra World Equity Review is also smoking hot in our predictions!! From FDA Drug Approvals and Trials to Potential Joint Ventures, Mergers, Buyouts, Acquisitions and Lawsuit Settlements..... get THE Scoop, always on the cutting edge of BIG Breaking News. Sierra World Equity Review covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks on the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. Sierra World Equity Review made more correct calls in the last 23 months than all other Stock Reviews COMBINED!! We have had excellent success but please remember to always do your own due diligence in regards to any stocks we feature! Good luck in all your trades! For the latest updates on these stocks follow Sierra on Twitter